How China gallops on Covid vaccines. The Sinopharm case
In China, Sinopharm, a company working on two Covid-19 vaccines, is going to mass production.
In China, 13 vaccine candidates against Covid-19 are in the clinical phase. Four of these have reached phase 3, the final one: the doses administered, at the moment, have not reported serious side effects.
Sinopharm, the main Chinese state company active in the healthcare sector, which has developed two drugs, is ready to launch mass production.
All the details.
THE VACCINE RACE IN CHINA
Let's start with the general numbers, spelled out in a press conference by Tian Baoguo , deputy director of the Ministry of Science and Technology: in China there are "13 vaccines against Covid-19 in the clinical phase, four of which have entered the third phase, the last ".
"The doses administered so far have involved 60,000 people, have not reported serious side effects and all vaccine candidates have been shown to be safe," added Baoguo, stressing, therefore, the safety of the antidotes developed.
CHINA FOLLOWS WHO RULES
On the administration of vaccines, China follows WHO rules, specifies the Global Times. Only people with high exposure to Covid-19 received emergency vaccines. And at the moment they have not shown any serious contraindications. The Beijing government, the newspaper denies, has not yet made the coronavirus vaccines available to the public.
"Emergency use of candidate vaccines has followed a rigorous review and approval procedure in China and complies with WHO rules and, so far, all those who received vaccines under the emergency use plan have not showed serious adverse reactions, ” said Zheng Zhongwei, an official of the Chinese National Health Commission.
SINOPHARM'S (PRODUCTIVE) INCREASE
Among the vaccines included in the emergency program are the two drugs developed by Sinopharm, a group listed on the Hong Kong Stock Exchange and born from the joint venture between the state-owned China National Pharmaceutical Group and the giant Fosun. The Chinese company, which currently has third-phase clinical trials underway in 10 foreign countries, including the United Arab Emirates, Argentina, Egypt and Peru, involving over 50,000 volunteers, is moving into mass production.
Sinopharm "is ready to begin large-scale production of vaccines to ensure sufficient and safe supplies," said president Liu Jingzhen, according to the state-owned English-language TV CGTN. "After obtaining the safety and security data from the Phase III clinical trial, the vaccine can be marketed after review and approval," Jingzhen said .
THE IMMUNE RESPONSE OF SINOPHARM VACCINES
Already the old trial phases had shown the efficacy of Sinopharm's vaccines. The first and second phase of clinical trials for the two vaccines, conducted in China, had enrolled 4,064 volunteers and activated an effective immune response in all candidates, writes the Chinese press.
PRODUCTION
Sinopharm, the leading Chinese state-owned healthcare company with R&D, manufacturing, logistics and pharmaceutical chains, expects to produce 610 million doses of vaccines by the end of the year, confirmed Zheng Zhongwei, head of the Covid-19 vaccine development task force. In 2021, the production capacity is expected to rise to 1 billion doses.
The Chinese has built, writes Reuters, two new production plants.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/come-la-cina-galoppa-sui-vaccini-anti-covid-il-caso-sinopharm/ on Tue, 20 Oct 2020 08:40:58 +0000.